Back to News
Market Impact: 0.2
SciSparc: Subsidiary NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations
Source: GlobeNewswire
Patents & Intellectual PropertyHealthcare & Biotech
NeuroThera filed U.S. patent applications covering proprietary combinations of its PEA technology with LSD, ketamine and ibogaine. The proposed therapeutic applications include depression, PTSD and substance-use disorders, potentially strengthening the company’s intellectual-property position in psychedelic-based mental-health treatments.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
More News
- OpenAI’s agent hacked Australia’s Medicare website—the latest rogue AI incident that the company didn’t know about for months
- Australia says OpenAI agent hacked Medicare portal
- US aviation sanctions disrupt Iran flights, push travellers overland
- Meta Debuts $349 Camera-Free Ray-Bans and Brings Muse to Glasses
- OpenAI agents ‘infiltrated Australian government website’
- U.S. demand for Novo Nordisk’s weight loss drugs is so huge that the Danish central bank just doubled the nation’s entire growth forecast